Literature DB >> 3010929

Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure.

H Ikram, M W Webster, M G Nicholls, G R Lewis, A M Richards, I G Crozier.   

Abstract

Three cases are described of severe congestive heart failure which failed to respond to digitalis, high doses of loop diuretics, and converting-enzyme inhibitors. The addition of spironolactone produced a substantial diuresis associated with clinical and radiological improvement in each case. Although a reversible deterioration in renal function was observed, this drug combination represents a therapeutic option in end-stage heart failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3010929     DOI: 10.1111/j.1445-5994.1986.tb01119.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  3 in total

1.  Management of congestive heart failure.

Authors:  O M Jolobe
Journal:  Postgrad Med J       Date:  1997-12       Impact factor: 2.401

2.  ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure.

Authors:  John W Funder
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

Review 3.  Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis.

Authors:  Nicolas M Berbenetz; Marko Mrkobrada
Journal:  BMC Cardiovasc Disord       Date:  2016-12-01       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.